Michael Ehlers, Biogen via Youtube
October 1, 2019 08:33 AM EDTUpdated 10:18 AM
R&D

Michael Ehlers jumps a list­ing ship, turn­ing to VC and star­tups as a dam­aged Bio­gen taps long­time vet Al San­drock to take his place

John Carroll

Editor & Founder

Al San­drock Bio­gen

Just a lit­tle more than 3 years af­ter Michael Ehlers took the lead job as glob­al head of R&D for the now deeply trou­bled Bio­gen, he’s jump­ing ship. And CEO Michel Vounatsos is nam­ing CMO Al San­drock, the ar­chi­tect of a deeply flawed pipeline strat­e­gy, as his re­place­ment.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times